Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Crabtree ... £30m ? ...you are assuming that everyone in the supply chain worldwide works for nothing ! ..... I still say a good company but why the ramping hype ?
Saint Tropez - it’s not quite that simple. The existing IDH business already covers all fixed costs, not true of many of the more speculative covid punts. That means that all the incremental gross margin made on additional business such as this falls straight to the bottom line. I suspect at the end of the day, any covid passport that is issued will need to be independently verified in a lab using accurate, tried and trusted equipment - IDH is an established player. 600 machines is a decent footprint, if more need to be built - that’s no bad thing for IDH.
I wonder if the company will start doing pr now
Entirely depends whether the 210p close was the right price to begin with. £5 equates to an ev:sales of 3x. If the company is going to grow - and today’s news suggests it will - that’s not demanding for a high margin growth stock in the right place at the right time. I’ve heard stranger predictions. Atb
it says over 600 labs how many machines do they have in each lab?
IDS-iSYS analysers are already installed in over six hundred laboratories worldwide, including many NHS hospitals. The majority of these analysers are in territories which use the CE mark as the basis for regulatory approval. Each system is capable of running over 10,000 tests per month.
Look at the Countries
https://support.ce-check.eu/hc/en-us/articles/360014076911-In-which-countries-is-the-CE-marking-required-
There isn't another antibody test out there with such high sensitivity. Let alone give a quantitative output. Even at this price the company this little gem has a quarter of its SP as cash and equivalents!
I agree p, jarv. The science here is evidently great, strong market positions. But the PR is the biggest joke in the market! I emailed them a couple of months back regarding what they were doing about covid - no response. They are an immunological diagnostics company - immunodiagnostics plc - that has had b*gger all to say during the largest sea change to impact its industry in years.
If a system is in place and apparently is present in 600 labs, each system can test 10k per month = 6M tests per month with an actual amount of antibody present in each sample with a test result in 25 min
Closing cash and cash equivalents were £27.6m at 31 March 2020 (31 March 2019: £27.7m).
By comparison I think ODX has about £1M! And no approved test at present and pretty much the same (£92 v £89M) which is interesting
“We are a specialist in-vitro diagnostic solution provider to the clinical laboratory market,” begins Jaap Stuut, the Group CEO of Immunodiagnostic Systems (IDS). His firm and proud statement is equally substantiated by the value that the company has created over the years. IDS has not only manufactured more than 1000 systems. Last year IDS launched three new CE marked automated assays, it has also partnered with Technogenetics SRL, which has allowed the company’s global sales rights to extend in the automated autoimmune and infectious disease assay range. “Our core focus is not only to develop, produce, manufacture, and distribute products, but also to increase the diagnostic value, and the last year has been an example of this” says Stuut.
Founded in 1977, for IDS, it has been a tale of many years dedicated toward development and provision of innovative, automated, and manual assays. The company’s development focus has been in the clinical areas of bone and calcium metabolism, growth, hypertension, and chronic kidney disease. To this end, the company has designed the IDS-iSYS automated system with the flexibility to accommodate unique and challenging requirements, which ultimately brings testing efficiency and high-end quality to specialty immunoassay testing. Above all, it is the close-knit partnership that IDS has maintained with its clients that has propelled it toward success. Stuut states an example, “By communicating with our customers, we know that there is a need for specialty immune assays that most other companies do not develop.”
IDS produces both manual and automated assays. The automated side of the business also comprises of the sale or placements of the IDS instruments, IDS also sells manual assays to laboratories through the manual segment. The main reason behind this business process is the company’s aim to serve the labs which don’t have the size to warrant the placement of a closed automated system.
Additionally, a laboratory may compliment their core lab system with a complementary instrument or ELISA technique for manual testing if these tests are not offered by the core lab system supplier. IDS is a supplier of both the automated and manual ELISA assays and can fulfil specialty immunoassay needs for laboratories.
Being a niche player in the in-vitro diagnostic solution arena, IDS’s system is one of the best random-access instruments in its segment and performance category. Further, the company offers its OEM customers state-of-the-art technology ‘off the shelf’. “They do not have to go through the multi-year process of designing a new instrument from scratch in cooperation with companies specialized in this business,” states Stuut. “The key to success in this business unit is continued progress by our R&D teams in developing new instrument technology which can be monetized by our commercial team.”
IDS is one of the companies in the market offering random access system solutions with the experience of an IVD
“There isn't another antibody test out there with such high sensitivity.”
Yes there are - do some more research.
The problem with buying shares here is that you might not get a sales update until the final results for 2020 are released next year!
where are they then name them